Advanced Markets form the foundation of Biocon Biologics’ global growth strategy, contributing over 75% of our total revenues. In these highly regulated and competitive geographies, we are expanding access to high-quality, affordable biosimilars that improve health outcomes for patients managing chronic conditions such as diabetes, cancer, and autoimmune diseases.

We have built a strong commercial presence across the U.S., Canada, and the Big 5 European countries — Germany, France, the UK, Spain, and Italy — with a robust portfolio spanning key therapy areas. Our self-led model in 21 markets, complemented by strategic partnerships in 16 others, has enabled us to achieve double-digit market shares in several countries. Through consistent performance and a patient-centric approach, we have built strong brand equity among healthcare professionals, partners, and patients — positioning us for sustained growth and expanded access globally.